Compass Therapeutics, Inc. (CMPX)

Market Cap	983.58M
Revenue (ttm)	n/a
Net Income (ttm)	-65.81M
Shares Out	177.86M
EPS (ttm)	-0.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,136,264
Open	5.59
Previous Close	5.54
Day's Range	5.48 - 5.74
52-Week Range	1.33 - 5.86
Beta	1.26
Analysts	Strong Buy
Price Target	13.44 (+143.04%)
Earnings Date	Nov 5, 2025

About CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPX
• Website: https://www.compasstherapeutics.com

Analyst Forecast

According to 10 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price target is $13.44, which is an increase of 143.04% from the latest price.

Price Target

$13.44

(143.04% upside)

Analyst Consensus: Strong Buy